Skip to main content

Publication: PR17 retrospective analysis and OV25 secondary analysis

Two Science Direct publications - A PR17 retrospective analysis and OV25 secondary analysis
PR17 Retrospective Analysis
ENZAMET randomised 1125 participants with metastatic hormone-sensitive prostate cancer to receive enzalutamide or a standard nonsteroidal antiandrogen (NSAA) combined with testosterone suppression with or without docetaxel. Enzalutamide demonstrated superior progression-free and overall survival (OS). Radiographic progression without prior/concurrent prostate-specific antigen progression (discordant progression; DP) portends poor outcomes. Researchers wanted to determine the frequency of DP in ENZAMET and the impact of enzalutamide on disease-state transitions.
 
Inderjeeth A-J, Martin AJ, Zielinski RR, Begbie S, Cheung L, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott RS, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson AH, Vera-Badillo F, Williams SG, Thomas H, Yip S, Zhang AY, Chi KN, Stockler MR, Sweeney CJ, Davis ID. Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). European Urology Oncology 9: 396-403. 2026.
 
 
OV25 Secondary Analysis
 
The OV25 trial is a randomized, double-blind, placebo-controlled, phase II study evaluating ASA for ovarian cancer prevention in women with germline BRCA 1/2 mutations (NCT03480776). Clonal hematopoiesis (CH) is a common phenomenon associated with an increased risk of hematological cancers. Its prevalence and relevance in BRCA carriers are yet to be characterized. Researchers wanted to evaluate the prevalence and characteristics of CH in women with BRCA1/2 mutations undergoing risk-reduction surgery.
 
Poster at Society of Gynecological Oncology Annual Meeting on Women's Cancer, 10-13 April, 2026, San Juan, Puerto Rico
Lheureux S, Abelson S, Bauer S, Fabre M, Bernardini M, Plante M, Provencher D, Brand A, Cohen P, Dawson L, Lackie E, Lee YC, Altman A, Lapointe-Milot K, Friedlander M, Brar H, Kim R, Brenton J, Reynolds A, Tu D, Parulekar W, Pugh T, Oza A. Prevalence of clonal hematopoiesis (CH) in BRCA 1/2 mutation carriers enrolled in a randomized prevention trial of acetylsalicylic acid (ASA) – The STICS and STONES study (CCTG-OV25). SGO Annual Meeting on Women's Cancer. Gynecologic Oncology 208 S335-S336. 2026.